Showing results (491-500 of 513) with videos related to

Sort By:
Pageof 52
Lancet (London, England)|December 10, 2022
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)Joseph F Merola, Robert Landewé, Iain B McInnes, et al.
Arthritis Care & Research|October 20, 2019
Development of a Set of Lupus-Specific, Ambulatory Care-Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus StudyCandace H Feldman, Cameron Speyer, Rachel Ashby, et al.
The British Journal of Dermatology|May 11, 2018
Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasisC Ryan, A Menter, L Guenther, et al.
Plos One|April 6, 2017
A study of the transferability of influenza case detection systems between two large healthcare systemsYe Ye, Michael M Wagner, Gregory F Cooper, et al.
Annals of the Rheumatic Diseases|August 6, 2026
Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trialDésirée van der Heijde, Philip J Mease, Carle Paul, et al.
Journal of Drugs in Dermatology : JDD|December 5, 2023
International Dermatology Outcome Measures (IDEOM) - Report from the 2022 Annual MeetingKathryn Lee, Michael J Woodbury, Melissa Peri Zundell, et al.
JACC. Cardiooncology|February 18, 2026
Systemic Manifestations and Mortality Risk in Transthyretin V142I Variant Carriers: A Million Veteran Program AnalysisKonstantinos Sideris, Tyler J Nelson, Lina Brinker, et al.
JAMA Dermatology|June 22, 2018
Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic ReviewAdam R Ford, Michael Siegel, Jerry Bagel, et al.
BMJ Open|December 23, 2022
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trialRebecca H Haberman, Katrina A MacFarlane, Sydney Catron, et al.
The Journal of Clinical Investigation|July 1, 2025
Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flaresJames G Krueger, Mrinal K Sarkar, Mark G Lebwohl, et al.
Pageof 52